Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Shire PLC Add to portfolio

LON100:SHP, Dec 14, 11:04 UTC

Latest LON100:SHP News

Filter your feed

Apply Filter

Wednesday, December 12


News

Voluntary Planning Agreement signed with Shire Councils of Lachlan, Forbes and Parkes Australian Stock Exchange:CLQ.AX

SHP

December 12, 2018 18:39 ET | Source:Clean TeQ Holdings Limited. Clean TeQ will also contribute approximately A$340,000 each year to fund maintenance of the road network it will use, with an additional investment to upgrade various roads and intersections. Council looks forward to Clean TeQ becoming a valued corporate citizen of our local government area.”. Forbes Shire Council Mayor Cr Phyllis Miller OAM said, "Forbes Shire Council is pleased to partner with Clean TeQ and our neighbouring councils in this unique project for Central West NSW. The VPA will provide an opportunity for Forbes Shire Council to implement unique community enhancement projects over the lifespan of the mine." Parkes Shire Mayor Cr Ken Keith OAM said, "Today marks a major milestone in the development of this nationally-significant mine, and we are delighted to sign the VPA alongside our colleagues from the Lachlan and Forbes Shires. "Not only will the project generate high-value employment for the region but will also be a supplier of ethically mined nickel and cobalt for the electric vehicle battery market, which is so important for vehicle emission reduction. "The Community Enhancement Funds will be invested in the Trundle community, with the next round allocated to the community of Tullamore and to investigate childcare needs across the Shire. An additional provision of the VPA will ensure the road network is safe and well maintained." Clean TeQ Sunrise is one of the largest cobalt deposits outside of Africa, and one of the largest and highest-grade accumulations of scandium ever discovered.

Read Full Details

Topics:
  • Business
  • Financial

Tuesday, December 11


News

Shire, Abbott Labs May Pace Healthcare Stocks in 2019

BSX SHP +1 more BSX SHP ABT

Shire is a pharmaceutical company, with a wide range of products approved for use around the world. Some of the more familiar drugs the company produces include Adderall, prescribed for adult ADD, and Pentasa, used to treat Crohn's and other inflammatory bowel diseases. The company possesses both strength and weakness, and both are evident in the most recent quarterly report.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Thursday, December 06


News

Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger

SHP

Earlier the same day, Takeda’s shareholders also gave a green signal to the proposed merger. Takeda stated that at least 88% of shareholders had voted to approve the acquisition at a shareholder meeting held in Osaka, Japan. The Takeda/Shire merger deal was announced in May this year when Shire accepted the buyout offer from Takeda, valuing the company at 47 pounds per share or around 46 billion pounds ($62 billion) in total. The acquisition of Shire will accelerate Takeda’s transformation by bringing together Takeda and Shire’s complementary positions in gastroenterology (GI) and neuroscience.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Guillain-Barr Syndrome Treatment Markets: Global Outlook to 2023 with CSL, Grifols, Octapharma, Shire and Kedrion Dominating

SHP

Guillain-Barr Syndrome Treatment Markets: Global Outlook to 2023 with CSL, Grifols, Octapharma, Shire and Kedrion Dominating. Dublin, Dec. 06, 2018 (GLOBE NEWSWIRE) -- The "Global Guillain-Barré Syndrome Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering. The Guillain-Barr syndrome treatment market will register a CAGR of more than 5% by 2023. The recent approvals of novel immunoglobulins from regulatory bodies are expected to propel the growth of the global Guillain-Barr syndrome treatment market during the forecast period.Currently there is no cure for Guillain-Barr syndrome.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Takeda clears crucial hurdle as investors back Shire deal

SHP

Takeda Pharmaceutical has won shareholder approval for its $59bn (€52bn) takeover of Shire, creating a global powerhouse that has a stronger drugs pipeline but is also saddled with massive debt. The high debt levels were a significant concern for Takeda shareholders who gathered at an extraordinary meeting in Osaka, western Japan, although almost 90pc of them voted to approve the deal as expected. "I want to keep my Takeda shares into the future, but now I am worried about further declines in the share price," said Satoshi Ito, a 75-year-old shareholder. Shire power: A woman sits in the entrance hall of Takeda Pharmaceutical’s global HQ in Tokyo, Japan – the company’s takeover of Shire is the biggest overseas acquisition by a Japanese company.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Wednesday, December 05


News

Shareholders agree to Takeda's $60bn Shire acquisition

SHP

Japanese drug giant Takeda's mammoth $60-billion takeover of Irish pharmaceuticals firm Shire has been approved by both sets of shareholders, the pair said Wednesday. The deal, which will create one of the world's top 10 drug companies, caps a lengthy courtship by Takeda of its larger rival as it seeks to expand overseas. Analysts have said the buyout would be a smart move by Takeda as it looks to diversify, and could pay off in the long-term, but it has also raised concerns that the Japanese firm could be overextending itself financially. Takeda plans to finance the 46-billion-pound ($58.4 billion) buyout through issuing new shares in exchange for Shire stock, bank loans and bond issuance.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Takeda and Shire shareholders back mammoth £46bn deal

SHP

Japanese drugs firm Takeda has won shareholder approval for its £46 billion acquisition of Shire, paving the way for the deal to create one of the biggest pharmaceutical firms in the world. Christophe Weber, Takeda’s president and chief executive, said: “With shareholder approval secured, we are looking forward to closing the acquisition in the coming weeks to create a more competitive, agile, highly profitable, and therefore more resilient company, poised to deliver highly innovative medicines and transformative care to patients around the world.”. Shares in Shire, which have soared since the deal was announced, rose another 3% on news of the shareholder approval. Takeda reached a deal in May to buy Irish rival Shire for £49.01 a share. But there had been concerns the company is taking on too much debt to finance the deal and speculation had mounted ahead of the vote that some investors may vote down the deal.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Takeda shareholders give greenlight for £46 billion Shire deal

SHP

Takeda Pharmaceutical has secured support from its shareholders to proceed with its £46 billion acquisition of Shire. ‘With shareholder approval secured, we are looking forward to closing the acquisition in the coming weeks to create a more competitive, agile, highly profitable, and therefore more resilient company, poised to deliver highly innovative medicines and transformative care to patients around the world.’. The deal is a massive step forward for the Japanese drug marker that will take Takeda from a strong regional player in the Asia to one with a global presence, particularly in the US, which represents the largest pharmaceutical market in the world. The £46 billion price tag for Shire is massive, with Takeda rumoured to be funding the deal via a mix of new shares and debt, with the Japanese drug maker funding around £25 billion via a rights issue and around £24 billion in bank loans.

Read Full Details

Story Sources

ig.com ig.com
Topics:
  • Business
  • Financial
News

Is the Options Market Predicting a Spike in Shire (SHPG) Stock?

SHP

That is because the Dec 7, 2018 $150.00 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy. What do the Analysts Think? Clearly, options traders are pricing in a big move for Shire shares, but what is the fundamental picture for the company?

Read Full Details

Topics:
  • Business
  • Financial
News

Takeda wins shareholder approval of $59-billion Shire takeover

SHP

Takeda Pharmaceutical has won shareholder approval for its $59 billion takeover of London-listed Shire, creating a global powerhouse that has a stronger drugs pipeline but is also saddled with massive debt. Takeda will be joining the ranks of the world’s top 10 drugmakers and gaining expertise in rare diseases through the deal, the biggest overseas acquisition by a Japanese company. The company’s high debt levels were a top concern for Takeda shareholders who gathered at an extraordinary meeting in Osaka, western Japan, although almost 90 per cent of them voted to approve the deal as expected. Toshiba’s acquisition of Westinghouse over a decade ago and Japan Post Holdings’ $4.9 billion bet on Toll Holdings are widely seen as examples of many Japanese companies having paid high valuations in cross-border deals only to face massive writedowns later. But they also said Takeda has little choice but to seek growth abroad, with industry pressure to gain access to cutting-edge treatments amid declining revenue from older drugs that must compete with cheaper generics. Even with the acquisition of Shire, some said Takeda will need to bolster its lineup of experimental therapies to compete in the longer term.

Read Full Details

Topics:
  • Business
  • Health
  • Financial